Monday 18 May 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • MitoKor Identifies Genetic Mutations, AD Link?

MitoKor Identifies Genetic Mutations, AD Link?

4 May 1997

- Scientists from MitoKor have identified mutations in the cytochromeC oxidase genes of mitochondrial DNA which, they say, lead to defects in energy metabolism and may account for a large number of late-onset Alzheimer's disease cases. As mitochondrial DNA is maternally inherited, they add, this may explain why the risk of AD increases when a maternal relative has the disease. Findings are published in the April 29 issue of the Proceedings of the National Academy of Sciences.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

The week in pharma: action, reaction and insight – week to May 15, 2026
Pharmaceutical
The week in pharma: action, reaction and insight – week to May 15, 2026
17 May 2026
Biotechnology
FDA greenlight for Enhertu in two new indications
16 May 2026
Biosimilars
FDA approves first interchangeable biosimilars to Simponi and Simponi Aria
16 May 2026
Pharmaceutical
Kelly Sanderson Schrems succeeds Steve Hopkinson as AbbVie UK GM
15 May 2026
Pharmaceutical
FDA puts clinical hold on Aardvark’s IND
15 May 2026
Pharmaceutical
Tempus AI expands collaboration with BMS
15 May 2026
Pharmaceutical
NICE backs Winrevair for PAH
15 May 2026


Company Spotlight

Aardvark Therapeutics
A clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of metabolic diseases, inflammation, and other indications.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze